Abstract
Combining nanotechnology and bioorthogonal chemistry for theranostic strategies offers the possibility to develop next generation nanomedicines. These materials are thought to increase therapeutic outcome and improve current cancer management. Due to their size, nanomedicines target tumors passively. Thus, they can be used for drug delivery purposes. Bioorthogonal chemistry allows for a pretargeting approach. Higher target-to-background drug accumulation ratios can be achieved. Pretargeting can also be used to induce internalization processes or trigger controlled drug release. Colloidal gold nanoparticles (AuNPs) have attracted widespread interest as drug delivery vectors within the last decades. Here, we demonstrate for the first time the possibility to successfully ligate AuNPs in vivo to pretargeted monoclonal antibodies. We believe that this possibility will facilitate the development of AuNPs for clinical use and ultimately, improve state-of-the-art patient care.
| Originalsprog | Engelsk |
|---|---|
| Artikelnummer | e202201847 |
| Tidsskrift | Chemistry - A European Journal |
| Vol/bind | 28 |
| Udgave nummer | 61 |
| Antal sider | 10 |
| ISSN | 0947-6539 |
| DOI | |
| Status | Udgivet - 2022 |
Bibliografisk note
Funding Information:The authors wish to thank the staff at the PET and Cyclotron unit for expert technical assistance. We also want to thank Tagworks Pharmaceuticals for providing CC49‐TCO. This project has received funding from the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska‐Curie grant agreement No. 813528. C.B.M.P. was supported by BRIDGE ‐ Translational Excellence Program at the Faculty of Health and Medical Sciences, University of Copenhagen, funded by the Novo Nordisk Foundation (grant agreement no. NNF18SA0034956).The Research Council for Independent Research (grant agreement no. 8022‐00358B) is further acknowledged.
Publisher Copyright:
© 2022 The Authors. Chemistry - A European Journal published by Wiley-VCH GmbH.